Camurus AB Sweden

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU

First subcutaneous, once-monthly octreotide for treatment of acromegalyFor convenient self-administration with a pre-filled autoinjector penand LinkedIn.

References

Oczyesa® SmPC.Colao A., et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20.Webb SM, et al. Quality of Life in Acromegaly. Neuroendocrinology. 2016;103(1):106-111.Fleseriu M., et al Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022 Nov;10(11):804-826. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1671 Ferone, D., et al. J Clin Endocrinol Metab. Published 8 October, 2024. Press release 15 July, 2024: https://www.camurus.com/media/press-releases/2024/camurus-announces-positive-phase-3-results-from-the-acroinnova-2-study-of-octreotide-sc-depot-cam2029-in-acromegaly-patients/ Crisafulli S., et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinology. 2021; 185:251-63.Summary of Product Characteristics, Sandostatin LAR 20 mg: https://assets.hpra.ie/products/Human/22656/Licence_PA0896-028-005_03012024152159.pdf

This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 11.30 am CET on 1 July 2025.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/camurus-ab/r/camurus--oczyesa--receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu,c4164149

The following files are available for download:

https://mb.cision.com/Main/13456/4164149/3539788.pdf

Press release

 

View original content:https://www.prnewswire.co.uk/news-releases/camurus-oczyesa-receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu-302495549.html